Skip to content

The effect of rosehip supplement consumption on fatty liver

Assessment of rosehip supplement consumption on fatty liver grade and liver enzymes in comparison with control group in patients with fatty liver

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT201410265968N5
Enrollment
78
Registered
2017-10-15
Start date
2017-10-23
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

fatty liver. Fatty (change of) liver, not elsewhere classified Nonalcoholic fatty liver disease [NAFLD]

Interventions

Intervention 1: Intervention group will receive two cans of rosehip supplement for four weeks consume. The amount of consumption of supplement will be 5 gram daily. Each supplement contains 1 gram of
Treatment - Drugs
Placebo
Intervention group will receive two cans of rosehip supplement for four weeks consume. The amount of consumption of supplement will be 5 gram daily. Each supplement contains 1 gram of rosehip flour. P
Control group will receive two cans of placebo for four weeks consume. The amount of consumption of placebo will be 5 gram daily. Each placebo contains 1 gram of corn flour. Patients will be advised t

Sponsors

Brain and Spinal injury Research Centre
Lead Sponsor

Eligibility

Sex/Gender
All
Age
17 Years to 69 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: 1.Age between 18 and 70 years 2.Fatty liver disease. Exclusion criteria: 1. Alcohol consumption 2.Smoking 3.taking certain medication, such as blood pressure medications, Insulin sensitivity enhancers, statins, hepatotoxic drugs such as Phenytoin, tamoxifen, lithium and supplements 4. Acute liver disorders such as Hepatitis B and C, liver transplantation, biliary disease known as autoimmune disease, cancer, inherited disorders affecting liver condition (iron and copper storage disease) and other disease 5.Failure to sign the ethical consent.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Fatty Liver grade. Timepoint: At the baseline and then after 4 months. Method of measurement: sonography.;Liver enzymes, SGOT and SGPT. Timepoint: At the baseline and then after 4 months. Method of measurement: blood test.

Secondary

MeasureTime frame
Lipid Profile. Timepoint: At the baseline and then after 4 months. Method of measurement: blood test.

Countries

Iran (Islamic Republic of)

Contacts

Public Contactsamira tabrizian

Brain and Spinal Injury Research Centre

samira.tabrizian93@gmail.com+98 21 6658 1560

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026